Cargando…

Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells

Dipeptidyl peptidase (DPP)-4, a molecular target of DPP-4 inhibitors, which are type 2 diabetes drugs, is expressed in a variety of cell types, tissues and organs. DPP-4 has been shown to be involved in cancer biology, and we have recently shown that a DPP-4 inhibitor promoted the epithelial mesench...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shaolan, Fan, Yang, Kumagai, Asako, Kawakita, Emi, Kitada, Munehiro, Kanasaki, Keizo, Koya, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037814/
https://www.ncbi.nlm.nih.gov/pubmed/31991851
http://dx.doi.org/10.3390/ijms21030805
_version_ 1783500509842243584
author Li, Shaolan
Fan, Yang
Kumagai, Asako
Kawakita, Emi
Kitada, Munehiro
Kanasaki, Keizo
Koya, Daisuke
author_facet Li, Shaolan
Fan, Yang
Kumagai, Asako
Kawakita, Emi
Kitada, Munehiro
Kanasaki, Keizo
Koya, Daisuke
author_sort Li, Shaolan
collection PubMed
description Dipeptidyl peptidase (DPP)-4, a molecular target of DPP-4 inhibitors, which are type 2 diabetes drugs, is expressed in a variety of cell types, tissues and organs. DPP-4 has been shown to be involved in cancer biology, and we have recently shown that a DPP-4 inhibitor promoted the epithelial mesenchymal transition (EMT) in breast cancer cells. The EMT is known to associate with chemotherapy resistance via the induction of ATP-binding cassette (ABC) transporters in cancer cells. Here, we demonstrated that deficiency in DPP-4 promoted chemotherapy resistance via the CXCL12/CXCR4/mTOR axis, activating the TGFβ signaling pathway via the expression of ABC transporters. DPP-4 inhibition enhanced ABC transporters in vivo and in vitro. Doxorubicin (DOX) further induced ABC transporters in DPP-4-deficient 4T1 cells, and the induction of ABC transporters was suppressed by either the CXCR4 inhibitor AMD3100, the mTOR inhibitor rapamycin or a neutralizing TGFβ (1, 2 and 3) antibody(N-TGFβ). Knockdown of snail, an EMT-inducible transcription factor, suppressed ABC transporter levels in DOX-treated DPP-4-deficient 4T1 cells. In an allograft mouse model, however, the effects of DOX in either primary tumor or metastasis were not statistically different between control and DPP-4-kd 4T1. Taken together, our findings suggest that DPP-4 inhibitors potentiate chemotherapy resistance via the induction of ABC transporters by the CXCL12/CXCR4/mTOR/TGFβ signaling pathway in breast cancer cells.
format Online
Article
Text
id pubmed-7037814
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70378142020-03-10 Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells Li, Shaolan Fan, Yang Kumagai, Asako Kawakita, Emi Kitada, Munehiro Kanasaki, Keizo Koya, Daisuke Int J Mol Sci Article Dipeptidyl peptidase (DPP)-4, a molecular target of DPP-4 inhibitors, which are type 2 diabetes drugs, is expressed in a variety of cell types, tissues and organs. DPP-4 has been shown to be involved in cancer biology, and we have recently shown that a DPP-4 inhibitor promoted the epithelial mesenchymal transition (EMT) in breast cancer cells. The EMT is known to associate with chemotherapy resistance via the induction of ATP-binding cassette (ABC) transporters in cancer cells. Here, we demonstrated that deficiency in DPP-4 promoted chemotherapy resistance via the CXCL12/CXCR4/mTOR axis, activating the TGFβ signaling pathway via the expression of ABC transporters. DPP-4 inhibition enhanced ABC transporters in vivo and in vitro. Doxorubicin (DOX) further induced ABC transporters in DPP-4-deficient 4T1 cells, and the induction of ABC transporters was suppressed by either the CXCR4 inhibitor AMD3100, the mTOR inhibitor rapamycin or a neutralizing TGFβ (1, 2 and 3) antibody(N-TGFβ). Knockdown of snail, an EMT-inducible transcription factor, suppressed ABC transporter levels in DOX-treated DPP-4-deficient 4T1 cells. In an allograft mouse model, however, the effects of DOX in either primary tumor or metastasis were not statistically different between control and DPP-4-kd 4T1. Taken together, our findings suggest that DPP-4 inhibitors potentiate chemotherapy resistance via the induction of ABC transporters by the CXCL12/CXCR4/mTOR/TGFβ signaling pathway in breast cancer cells. MDPI 2020-01-26 /pmc/articles/PMC7037814/ /pubmed/31991851 http://dx.doi.org/10.3390/ijms21030805 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Shaolan
Fan, Yang
Kumagai, Asako
Kawakita, Emi
Kitada, Munehiro
Kanasaki, Keizo
Koya, Daisuke
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
title Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
title_full Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
title_fullStr Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
title_full_unstemmed Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
title_short Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
title_sort deficiency in dipeptidyl peptidase-4 promotes chemoresistance through the cxcl12/cxcr4/mtor/tgfβ signaling pathway in breast cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037814/
https://www.ncbi.nlm.nih.gov/pubmed/31991851
http://dx.doi.org/10.3390/ijms21030805
work_keys_str_mv AT lishaolan deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells
AT fanyang deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells
AT kumagaiasako deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells
AT kawakitaemi deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells
AT kitadamunehiro deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells
AT kanasakikeizo deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells
AT koyadaisuke deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells